The potential for vaccine against infection of the genital tract with Chlamydia trachomatis.
about
T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar-specific immune responses in infected humansA vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challengeIncreased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.A live and inactivated Chlamydia trachomatis mouse pneumonitis strain induces the maturation of dendritic cells that are phenotypically and immunologically distinct.Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positiveThe rôle of Chlamydia trachomatis in genital-tract and associated diseases.Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection.Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexesImmunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challengeChlamydia trachomatis control requires a vaccine.Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice.Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challengeVaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.Identification of immunodominant antigens by probing a whole Chlamydia trachomatis open reading frame proteome microarray using sera from immunized mice.Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarraysDevelopment of a Chlamydia trachomatis T cell Vaccine.Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells.Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccineInduction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein gene (omp1)Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge.Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge.Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.T lymphocyte immunity in host defence against Chlamydia trachomatis and its implication for vaccine development.Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in miceCorrelation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervixA multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ⁺ CMI responses protects against a genital infection in minipigsProteomic identification of immunodominant chlamydial antigens in a mouse modelVaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis.Novel Chlamydia muridarum T cell antigens induce protective immunity against lung and genital tract infection in murine models.Role of CD8(+)T cells in the host response to ChlamydiaLymphokine-mediated inhibition of Chlamydia replication in mouse fibroblasts is neutralized by anti-gamma interferon immunoglobulin.Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.Biophysical and stabilization studies of the Chlamydia trachomatis mouse pneumonitis major outer membrane proteinIdentification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatisAssessment of the role in protection and pathogenesis of the Chlamydia muridarum V-type ATP synthase subunit A (AtpA) (TC0582).Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis.Genetic profiling of dendritic cells exposed to live- or ultraviolet-irradiated Chlamydia muridarum reveals marked differences in CXC chemokine profiles.
P2860
Q24548785-7F99CEF0-94BD-4851-861C-B4C9B1436A5FQ28391567-320BCF64-75D7-4499-94EC-A9F15445D572Q33648677-BFFAD510-0BD7-4CA7-B9AE-D339E62C92A2Q33716068-A522313E-78AD-49A5-AF74-41A5684B72B2Q33826107-CC4332EA-303D-4D4D-BEE1-073F633AF846Q33847903-8D2A46F0-7B7D-4096-B9E7-9547E05F2707Q34001186-D9CD1407-76EA-4893-8C75-BD87FB1ED505Q34005217-3E0F713D-3E51-4B7D-B3C1-21167FF29956Q34009341-8BB43E0C-6133-4E61-8B7E-59DD91F98262Q34103774-008EB88C-84EE-42CE-8AF3-8E7FE7E4B951Q34103785-9D0453FE-1535-4BB4-ADA5-90927DA628B7Q34130795-141D23B6-DEE7-41A0-99F2-68B8FEDC7A85Q34194679-8125E049-1FD6-4C3A-9D8D-4EBD223D76E5Q34311438-3BFF0E54-221E-40DF-89E7-9582A357F0D7Q34484641-05D3BC33-0F89-439C-8E78-3C06C405B1A6Q34623193-C07B195E-8803-4C12-895D-0F2451813EE7Q34663987-2418426D-BA82-412E-8A67-7C7D493BE367Q34773772-41711F7E-C997-4B9F-B084-D5ECC93E8E78Q35042764-20AFE293-1C0E-4E2A-A78E-018C987C3D02Q35113308-5E1F69E0-6E40-4989-81C0-D888351BB406Q35529733-634EB783-B5D9-4E85-BA1A-65DE7584B9F9Q35532580-2B3EFBB6-BD51-427C-B5A5-5E33CCDB2CA2Q35553289-2BA67511-ED3B-40A7-B04F-B28DDB22F536Q35689196-0D4B6E14-A3AF-427E-A675-3D46EC951D8CQ35839422-B40182B0-171C-4003-8275-D81BFF846975Q35867557-2E0CE3F4-31BA-497F-A152-4E9254366923Q36347554-E1583D6B-E580-4C33-A7BC-1CB33E44B8DAQ36564785-19D9F473-4423-4C88-A512-41816E756BB7Q36619644-2D6412BC-71BF-4C89-925B-0EC414FA3ABBQ36827004-01059C1F-6B4F-41E6-AE1D-835B53B71B2EQ37087607-78C09ECB-9235-4768-9181-A7797B3FE0CBQ37093100-F4B564E6-9FFF-4647-9D8C-4B8FB674BCCFQ37101047-53021F5F-AB17-4533-8315-D918DA3AB394Q37341897-D7E0BE1D-A0F2-4143-AA8D-1A7C488FEA2BQ37376415-1DFC08B5-9A0E-4F3E-A577-75AC980169C7Q37419766-A53EC4E7-5080-4B51-8D91-12BE446B48D0Q37624678-4FDF306C-DBFA-426F-922F-53DFCE33863EQ37712799-93D01CDB-0F7F-46C6-A1D2-287EF6F11632Q37837221-03303A34-12FB-4467-BCF6-C843E4DE78D2Q37861014-9B33D9B8-5F86-4E5E-99D4-4BB392280599
P2860
The potential for vaccine against infection of the genital tract with Chlamydia trachomatis.
description
1978 nî lūn-bûn
@nan
1978 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1978 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
name
The potential for vaccine agai ...... ct with Chlamydia trachomatis.
@ast
The potential for vaccine agai ...... ct with Chlamydia trachomatis.
@en
type
label
The potential for vaccine agai ...... ct with Chlamydia trachomatis.
@ast
The potential for vaccine agai ...... ct with Chlamydia trachomatis.
@en
prefLabel
The potential for vaccine agai ...... ct with Chlamydia trachomatis.
@ast
The potential for vaccine agai ...... ct with Chlamydia trachomatis.
@en
P1476
The potential for vaccine agai ...... ct with Chlamydia trachomatis.
@en
P2093
P577
1978-04-01T00:00:00Z